AR104177A1 - SYSTEM FOR THE ADMINISTRATION OF DRUGS IN THE LAGRIMAL GLAND - Google Patents

SYSTEM FOR THE ADMINISTRATION OF DRUGS IN THE LAGRIMAL GLAND

Info

Publication number
AR104177A1
AR104177A1 ARP160100898A ARP160100898A AR104177A1 AR 104177 A1 AR104177 A1 AR 104177A1 AR P160100898 A ARP160100898 A AR P160100898A AR P160100898 A ARP160100898 A AR P160100898A AR 104177 A1 AR104177 A1 AR 104177A1
Authority
AR
Argentina
Prior art keywords
drug
day
skin
administration
eyelid
Prior art date
Application number
ARP160100898A
Other languages
Spanish (es)
Inventor
Oki Kenji
Asada Hiroyuki
Miyakazi Tatsuya
Inagaki Koji
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of AR104177A1 publication Critical patent/AR104177A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un sistema no invasivo para la administración de fármacos para suministrar eficientemente un fármaco a la glándula lagrimal que comprende administrar el fármaco a la piel del párpado una vez al día. Método. Reivindicación 9: El sistema de administración de fármacos de acuerdo con la reivindicación 8, caracterizado porque el agonista de receptores muscarínicos es betanecol o carpronio. Reivindicación 11: Un preparado para absorción transdérmica para suministrar de manera no invasiva un fármaco a la glándula lagrimal, caracterizado porque comprende la administración a la piel del párpado una vez al día. Reivindicación 21: Un agente terapéutico para el ojo seco que contiene un agonista de receptores muscarínicos, que comprende la administración a la piel del párpado una vez al día. Reivindicación 22: Un método para suministrar de manera no invasiva un fármaco a la glándula lagrimal de un sujeto, caracterizado porque comprende administrar el fármaco a la piel del párpado del sujeto una vez al día. Reivindicación 34: El uso de un fármaco en la elaboración de un preparado para absorción transdérmica para suministrar de manera no invasiva el fármaco a la glándula lagrimal, caracterizado porque el preparado para absorción transdérmica se administra a la piel del párpado una vez al día.A non-invasive system for the administration of drugs to efficiently deliver a drug to the tear gland comprising administering the drug to the skin of the eyelid once a day. Method. Claim 9: The drug delivery system according to claim 8, characterized in that the muscarinic receptor agonist is betanecol or carpronium. Claim 11: A preparation for transdermal absorption for non-invasively delivering a drug to the lacrimal gland, characterized in that it comprises administration to the skin of the eyelid once a day. Claim 21: A therapeutic agent for dry eye containing a muscarinic receptor agonist, comprising administration to the eyelid skin once a day. Claim 22: A method of non-invasively delivering a drug to the tear gland of a subject, characterized in that it comprises administering the drug to the skin of the subject's eyelid once a day. Claim 34: The use of a drug in the preparation of a preparation for transdermal absorption to non-invasively deliver the drug to the tear gland, characterized in that the preparation for transdermal absorption is administered to the skin of the eyelid once a day.

ARP160100898A 2015-04-03 2016-04-01 SYSTEM FOR THE ADMINISTRATION OF DRUGS IN THE LAGRIMAL GLAND AR104177A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015076890 2015-04-03

Publications (1)

Publication Number Publication Date
AR104177A1 true AR104177A1 (en) 2017-07-05

Family

ID=57005012

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100898A AR104177A1 (en) 2015-04-03 2016-04-01 SYSTEM FOR THE ADMINISTRATION OF DRUGS IN THE LAGRIMAL GLAND

Country Status (4)

Country Link
JP (1) JP2016196454A (en)
AR (1) AR104177A1 (en)
TW (1) TW201637648A (en)
WO (1) WO2016159351A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11759472B2 (en) 2017-11-21 2023-09-19 Cs Pharmaceuticals Limited Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
WO2019104207A2 (en) * 2017-11-21 2019-05-31 Axerovision, Inc. Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9102340D0 (en) * 1991-08-13 1991-08-13 Astra Ab PHARMACEUTICAL COMPOSITION CONTAINING CARBACHOL AND OTHERCHOLINERGIC SUBSTANCES
DE602005019724D1 (en) * 2004-05-21 2010-04-15 Senju Pharma Co OPHTHALMOLOGIC PERCUTANEOUS ABSORBENT PREPARATION CONTAINING A MUSCARIN RECEPTOR AGONIST
ES2830024T3 (en) * 2007-10-19 2021-06-02 Novartis Ag Compositions and methods for the treatment of macular edema
CA2719453A1 (en) * 2008-03-26 2009-10-01 Eric Donnenfeld Methods for improving lid margin and tear film function and treatment of lid margin disease using tetracycline family antibiotics

Also Published As

Publication number Publication date
WO2016159351A1 (en) 2016-10-06
JP2016196454A (en) 2016-11-24
TW201637648A (en) 2016-11-01

Similar Documents

Publication Publication Date Title
WO2015095772A3 (en) Formulations and methods for targeted ocular delivery of therapeutic agents
BR112017012706A2 (en) sunitinib formulations and methods for their use in the treatment of eye disorders
CL2017002939A1 (en) Topical pharmaceutical compositions
MX2017011280A (en) Topical regional neuro-affective therapy with cannabinoids.
EA201590902A1 (en) METHODS AND DEVICES APPLICABLE FOR THE TREATMENT OF EYE DISEASES IN HUMAN
MX2019001818A (en) Topical regional neuro-affective therapy with caryophyllene.
BR112016000177A2 (en) uses of a vegf antagonist in the treatment of chorioretinal and permeability neovascular diseases in pediatric patients, pre-filled syringe, kit and slow release formulation
BR112015025464A2 (en) stable, prolonged glp-1 / glucagon receptor coagonists for medical use
CL2019000245A1 (en) Moduladores nmda espiro-lactam and methods of use thereof.
MX2017016217A (en) Implantable drug delivery compositions and methods of use thereof.
MX2020005217A (en) Ophthalmic composition and delivery device thereof.
AR054249A1 (en) TREATMENT OF SKIN CONNECTIVE TISSUE DISEASES
MX2016008138A (en) System for the transdermal delivery of active ingredient.
AR096402A1 (en) METHORMIN AND DIHYDROCHERCETIN MEDICINAL PRODUCT
PE20181332A1 (en) METHODS OF SEDATION AND PARENTERAL FORMULATION FOR USE DURING THE TREATMENT OF CRITICAL CARE
EA201391689A1 (en) SYSTEM OF DELIVERY MEDICINE
AR072951A1 (en) USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THIS, FOR THE PREPARATION OF A MEDICINAL PRODUCT TO REGULATE THE LEVEL OF POTASSIUM IN THE BLOOD
BRPI0607172A2 (en) method for administering at least one pharmaceutically active substance to a patient, combining medicaments and using at least one pharmaceutically active substance for the manufacture of a combination of medicaments
BR112018000039A2 (en) single use release device
AR104177A1 (en) SYSTEM FOR THE ADMINISTRATION OF DRUGS IN THE LAGRIMAL GLAND
MX2017008000A (en) Single use injection system.
DOP2019000072A (en) PHARMACEUTICAL COMPOSITION WITH ANTAGONIST OF THE RECEIVER OF MINERALOCORTICOIDS AND ITS USE
UY31790A (en) USE OF DRONEDARONA TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS WITH ARRITMIA AND THAT HAVE AN INCREASE OF THE CREATININE LEVEL DUE TO THE ADMINISTRATION OF DRONEDARONA
WO2016036823A3 (en) Self-assembling drug delivery vehicles with ionically cross-linked drugs
AR074246A1 (en) DERIVATIVES OF 1-AMINO-ALQUILCICLOHEXANO FOR THE TREATMENT OF SOIL DISORDERS

Legal Events

Date Code Title Description
FB Suspension of granting procedure